In 2012, the WHO recommended seasonal malaria chemoprevention (SMC) to protect children aged 3 months to 5 years in areas of seasonal transmission of the disease in the Sahel region of sub-Saharan Africa. The medicine used for SMC, sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) is administered once a month throughout the rainy season, and in clinical trials has demonstrated a 75% reduction in the incidence of all malaria.1
In 2018, 81 million monthly courses of SPAQ treatment were shipped during the SMC season – estimated to have provided protection for more than 20 million children. Tenin is one of those children. Read her story below.